耐碳青霉烯类肠杆菌科细菌
Carbapenem-Resistant Enterobacteriaceae.
作者信息
Iovleva Alina, Doi Yohei
机构信息
Division of Infectious Diseases, University of Pittsburgh School of Medicine, Falk Medical Building, Suite 3A, 3601 Fifth Avenue, Pittsburgh, PA 15213, USA.
Division of Infectious Diseases, University of Pittsburgh School of Medicine, S829 Scaife Hall, 3550 Terrace Street, Pittsburgh, PA 15261, USA.
出版信息
Clin Lab Med. 2017 Jun;37(2):303-315. doi: 10.1016/j.cll.2017.01.005. Epub 2017 Mar 11.
Abstract
Carbapenem-resistant Enterobacteriaceae (CRE) have emerged as a major threat. Commonly used antibiotics are generally inactive against CRE. Therefore, timely detection of CRE is of paramount importance. Among CRE, those producing carbapenem-hydrolyzing β-lactamase enzymes (carbapenemase-producing Enterobacteriaceae) are particularly of concern because they tend to spread, and treatment is difficult. The carbapenemase groups most commonly encountered include KPC, NDM, and OXA-48. Treatment options are limited and include combinations of polymyxins, tigecycline, aminoglycosides, or carbapenems; newer agents with activity against CRE and better safety profiles are becoming available and will likely emerge as the preferred therapy.
摘要
耐碳青霉烯类肠杆菌科细菌（CRE）已成为一个重大威胁。常用抗生素通常对CRE无活性。因此，及时检测CRE至关重要。在CRE中，那些产生碳青霉烯水解β-内酰胺酶的细菌（产碳青霉烯酶肠杆菌科细菌）尤其令人担忧，因为它们易于传播且治疗困难。最常见的碳青霉烯酶类别包括KPC、NDM和OXA-48。治疗选择有限，包括多黏菌素、替加环素、氨基糖苷类或碳青霉烯类药物的联合使用；对CRE有活性且安全性更好的新型药物正在出现，并可能成为首选治疗方法。
相似文献
1
Carbapenem-Resistant Enterobacteriaceae.
Clin Lab Med. 2017 Jun;37(2):303-315. doi: 10.1016/j.cll.2017.01.005. Epub 2017 Mar 11.
2
Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia.
Clin Infect Dis. 2017 Feb 1;64(3):257-264. doi: 10.1093/cid/ciw741. Epub 2016 Nov 9.
3
Carbapenemase-producing Enterobacteriaceae.
Semin Respir Crit Care Med. 2015 Feb;36(1):74-84. doi: 10.1055/s-0035-1544208. Epub 2015 Feb 2.
4
In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline.
J Antibiot (Tokyo). 2016 Aug;69(8):600-4. doi: 10.1038/ja.2016.73. Epub 2016 Jun 29.
5
[Infectious diseases caused by carbapenemase-producing Enterobacteriaceae--a particular challenge for antibacterial therapy].
Med Monatsschr Pharm. 2014 May;37(5):162-72; quiz 173-4.
6
What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline.
Int J Antimicrob Agents. 2011 May;37(5):415-9. doi: 10.1016/j.ijantimicag.2011.01.012. Epub 2011 Mar 22.
7
Inactivation or inhibition of AcrAB-TolC increases resistance of carbapenemase-producing Enterobacteriaceae to carbapenems.
J Antimicrob Chemother. 2016 Jun;71(6):1510-9. doi: 10.1093/jac/dkw028. Epub 2016 Mar 5.
8
Clinical laboratory detection of carbapenem-resistant and carbapenemase-producing Enterobacteriaceae.
Expert Rev Anti Infect Ther. 2016 Aug;14(8):705-17. doi: 10.1080/14787210.2016.1206815. Epub 2016 Jul 11.
9
The management of multidrug-resistant Enterobacteriaceae.
Curr Opin Infect Dis. 2016 Dec;29(6):583-594. doi: 10.1097/QCO.0000000000000314.
10
New Delhi Metallo-beta lactamase (NDM-1) in Enterobacteriaceae: treatment options with carbapenems compromised.
J Assoc Physicians India. 2010 Mar;58:147-9.
引用本文的文献
1
Prevention of donation-related infections: investigating the use of antibiotics in the decontamination of preservation fluid for organ transplantation.
Front Cell Infect Microbiol. 2025 Jul 23;15:1572799. doi: 10.3389/fcimb.2025.1572799. eCollection 2025.
2
A Review of the Diagnostic Approaches for the Detection of Antimicrobial Resistance, Including the Role of Biosensors in Detecting Carbapenem Resistance Genes.
Genes (Basel). 2025 Jun 30;16(7):794. doi: 10.3390/genes16070794.
3
Phenotypic Detection of Extended-Spectrum β-Lactamase and Carbapenemase-Producing from Wastewater Treatment Plants in Ouagadougou, Burkina Faso.
Antibiotics (Basel). 2025 Jun 25;14(7):641. doi: 10.3390/antibiotics14070641.
4
Status of and comprehensive preventive strategies for multidrug-resistant organisms in Korea: a focus on carbapenem-resistant Enterobacterales.
Ewha Med J. 2024 Jul;47(3):e34. doi: 10.12771/emj.2024.e34. Epub 2024 Jul 31.
5
On the Difficulty to Detect Carbapenem Resistance in the Environment: Characterisation of Escherichia coli With Reduced Carbapenem Susceptibility Isolated in a French River.
Environ Microbiol Rep. 2025 Aug;17(4):e70162. doi: 10.1111/1758-2229.70162.
6
Genomic epidemiology and anti-biofilm mechanisms of Lactobacillus in ST11 carbapenem-resistant in China.
Front Microbiol. 2025 Jul 2;16:1619621. doi: 10.3389/fmicb.2025.1619621. eCollection 2025.
7
Resistance Profiling of Predominant Non- Enterobacteriaceae Isolated From Humans, Food Animals, and the Environment in the Fako Division of Cameroon.
Biomed Res Int. 2025 Jun 23;2025:3947539. doi: 10.1155/bmri/3947539. eCollection 2025.
8
Detection of KPC-Producing Carbapenem-Resistant Based on CRISPR Cas12a.
J Microbiol Biotechnol. 2025 Jun 12;35:e2502042. doi: 10.4014/jmb.2502.02042.
9
Integrating an LFA Carbapenemase Detection System into the Laboratory Diagnostic Routine: Preliminary Data and Effectiveness Against Enzyme Variants.
Diagnostics (Basel). 2025 Jun 5;15(11):1434. doi: 10.3390/diagnostics15111434.
10
Plasmid diversity of and isolates involved in two carbapenem-resistant outbreaks in a Swiss hospital.
Microbiol Spectr. 2025 Jul;13(7):e0328424. doi: 10.1128/spectrum.03284-24. Epub 2025 May 21.
本文引用的文献
1
Universal protocol for the rapid automated detection of carbapenem-resistant Gram-negative bacilli directly from blood cultures by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF/MS).
Int J Antimicrob Agents. 2016 Dec;48(6):655-660. doi: 10.1016/j.ijantimicag.2016.08.024. Epub 2016 Oct 20.
2
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.
Clin Infect Dis. 2016 Dec 15;63(12):1615-1618. doi: 10.1093/cid/ciw636. Epub 2016 Sep 13.
3
Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014.
Infect Control Hosp Epidemiol. 2016 Nov;37(11):1288-1301. doi: 10.1017/ice.2016.174. Epub 2016 Aug 30.
4
New Developments in Clinical Bacteriology Laboratories.
Mayo Clin Proc. 2016 Oct;91(10):1448-1459. doi: 10.1016/j.mayocp.2016.06.020. Epub 2016 Aug 21.
5
Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
J Antimicrob Chemother. 2016 Oct;71(10):2713-22. doi: 10.1093/jac/dkw239. Epub 2016 Jul 17.
6
Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae.
Virulence. 2017 May 19;8(4):403-416. doi: 10.1080/21505594.2016.1207834. Epub 2016 Jul 6.
7
High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center.
Clin Infect Dis. 2016 Oct 1;63(7):954-958. doi: 10.1093/cid/ciw398. Epub 2016 Jun 16.
8
Evaluation of different pretreatment protocols to detect accurately clinical carbapenemase-producing Enterobacteriaceae by MALDI-TOF.
J Antimicrob Chemother. 2016 Oct;71(10):2856-67. doi: 10.1093/jac/dkw208. Epub 2016 Jun 10.
9
Multisite Evaluation of Cepheid Xpert Carba-R Assay for Detection of Carbapenemase-Producing Organisms in Rectal Swabs.
J Clin Microbiol. 2016 Jul;54(7):1814-1819. doi: 10.1128/JCM.00341-16. Epub 2016 Apr 27.
10
New Delhi metallo-β-lactamase and extended spectrum β-lactamases co-producing isolates are high in community-acquired urinary infections in Assam as detected by a novel multiplex polymerase chain reaction assay.
Indian J Med Microbiol. 2016 Apr-Jun;34(2):173-82. doi: 10.4103/0255-0857.176853.
Zotero 插件